Efficacy of Upadacitinib After NECS in Vitiligo
ConditionVitiligo
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorJilin University
About this trial
The goal of this clinical trial is to investigate the efficacy of upadacitinib after NECS in participants with vitiligo. The main question it aims to answer is: whether the short time use of upadacitinib after NECS will improve NECS efficacy. Participants in the experimental group will receive upadacitinib after NECS, while Participants in the control group will receive NECS only.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participants who can sign the informed consent.
Participants aged 18-60 years (both men and women) at the time of signing the informed consent.
Non-segmented vitiligo
Disqualifiers
Any active skin lesions (e.g. psoriasis, dermatitis, skin ulceration, etc.) or skin infections (bacterial, fungal, viral, etc.) which may interfere with the assessment of vitiligo at screening.
Participants had a clinically significant infection (requiring hospitalization and parenteral treatment with antibiotics, antiviral agents, or antifungal agents for more than 3 days) within one month of the screening period or an active infection for which they were receiving treatment during the screening period.
Infected with HBV or HCV or HIV or syphilis.
Participants had active Tuberculosis or were receiving anti-Tuberculosis treatment, or had received anti-Tuberculosis treatment within 1 year.
Trial design
Design model
Parallel
Treatments tested in this trial
Upadacitinib 15 MG
DrugUpadacinib 15mg once daily for the 8 weeks after NECS
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: AExperimental treatment 1 intervention
Group B: BNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
T-VASI
Percentage of change from baseline in target lesion Vitiligo Area Scoring Index (T-VASI) at 6 months
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov